Inside Precision Medicine September 11, 2024
The obesity drug liraglutide (Novo’s Saxenda) is safe and effective in children aged 6 to 12 years, according to results of the SCALE Kids trial. The results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid this week. The study was simultaneously published in the New England Journal of Medicine. No medications are currently approved for the treatment of obesity of non genetic origin in children younger than 12.
According to the World Health Organization, in 2022, 37 million children under the age of five were overweight and over 390 million children and adolescents aged 5–19 years were overweight, including 160 million who were living with obesity.
In this study,...
Today's Sponsors
Today's Sponsor